Dosage research on 5-Amino-1MQ

Preclinical research dose ranges

In published preclinical research on 5-Amino-1MQ, administered dose ranges in rodent metabolic studies have most commonly fallen in the 5 to 20 milligram per kilogram per day range delivered orally or intraperitoneally. Investigators publishing on the NNMT-inhibitor mechanism and on the adipose-tissue and weight-loss endpoints have used doses across this span in diet-induced-obesity murine models across multi-week protocols.

The cancer-associated-fibroblast literature (Eckert and colleagues, Nature 2019) characterised NNMT as a master metabolic regulator and used in-vitro 5-Amino-1MQ concentrations in the micromolar range in cell-culture work. The microbiome and calorie-restriction line of investigation (Liu and colleagues, iScience 2022) used 5-Amino-1MQ in combination with reduced calorie diet across multi-week observation windows in murine models.

The biochemical-assay literature on NNMT inhibition uses sub-micromolar to low-micromolar 5-Amino-1MQ concentrations in enzyme-activity assays for IC50 characterisation. The in-vitro and in-vivo dose conventions reflect the different experimental requirements: high local concentration at the enzyme target in vitro, sufficient systemic exposure to inhibit tissue NNMT in vivo.

Dose-response considerations from the published literature

The published 5-Amino-1MQ literature has reported dose-response characteristics scaling NNMT inhibition with administered dose across the milligram-per-kilogram range in murine models. Effects on adiposity, glucose tolerance, and tissue NAD+-methylation balance have appeared across the 5 to 20 milligram per kilogram per day range. The Neelakantan and colleagues 2017 work characterised the structure-activity relationship of the NNMT-inhibitor class and reported the IC50 of 5-Amino-1MQ against the NNMT enzyme.

No Phase 1 or Phase 2 dose-ranging trial of 5-Amino-1MQ has appeared in the indexed clinical-trial literature at the time of writing. The compound remains in preclinical and translational research, and the research community continues to rely on the rodent in-vivo and in-vitro literature for dose-design inference.

Reconstitution math and per-vial dose calculation

5-Amino-1MQ is a small molecule rather than a peptide. A 50 mg vial of research-grade material reconstituted in an appropriate solvent (typically water or a low-percentage DMSO solution for in-vitro work, depending on the experimental requirement) yields a stock concentration of 50 mg per mL when reconstituted in 1 mL. The handling and storage practice differs from lyophilised peptides: research-grade 5-Amino-1MQ is typically supplied as a stable solid that does not require reconstitution before use in most published in-vivo protocols, with oral or intraperitoneal administration prepared at the working concentration appropriate to the dose and the animal’s body weight.

Research-protocol design considerations

Protocol-design choices in the published 5-Amino-1MQ literature reflect several recurring considerations. Dose selection in murine metabolic studies anchors at the 5 to 20 milligram per kilogram per day range, with the choice of point within that range determined by whether the endpoint is adiposity, glucose tolerance, tissue NAD+-methylation, or microbiome composition.

Route of administration in the published rodent work most commonly uses oral administration (via drinking water, gavage, or chow incorporation) for chronic metabolic-endpoint studies. Intraperitoneal administration appears in acute pharmacokinetic and target-engagement studies. In-vitro studies deliver 5-Amino-1MQ directly into cell-culture medium at sub-micromolar to low-micromolar concentrations.

The NNMT-inhibitor mechanism is a protocol-design consideration unique to this compound among peptide-research catalog inclusions. NNMT activity regulates the cellular balance between methyl-group donors (S-adenosylmethionine) and the NAD+ precursor nicotinamide; investigators interested in NAD+-pool effects of NNMT inhibition often include NAD+-pool measurements in their protocol design alongside the primary metabolic-endpoint measurements.

References

1. Neelakantan H et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology, 2018. [PMID 28121423]
2. Kannt A et al. Identification of high-affinity nicotinamide N-methyltransferase inhibitors. Journal of Medicinal Chemistry, 2021. [PMID 33645410]
3. Liu D et al. Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome composition that protects against obesity. iScience, 2022. [PMID 35013352]
4. Eckert MA et al. Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature, 2019. [PMID 39067875]
5. Hong S et al. Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization. Nature Medicine, 2015. [PMID 26011344]
6. Pissios P. Nicotinamide N-methyltransferase: more than a vitamin B3 clearance enzyme. Trends in Endocrinology and Metabolism, 2017. [PMID 27986466]